← Leaderboards
Alan C Rapraeger
University Of Wisconsin Madison
$12,873,938
Attributed
$12,873,938
Total exposure
10
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2005–22$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$12,873,938 · 10
By mechanism
R01$11,550,701 · 8
P50$1,298,237 · 1
R13$25,000 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Wisconsin Madison
Same institution · by research overlap
- Joseph W Kemnitz$11,486,212
- Stephen B. Kennedy$4,775,346
Others in their field
Top investigators on “Syndecan”
- Pyong Woo Park · Baylor College Of Medicine$19,694,248
- Michael Simons · Yale University$16,808,420
- Gordon William Laurie · University Of Virginia Charlottesville$9,632,610
- Bradley B Olwin · University Of Colorado At Boulder$7,763,454
- Ralph D Sanderson · University Of Arkansas Med Scis Ltl Rock$6,303,586
- Jeffrey D Esko · University Of California San Diego$6,056,594
Research focus
SyndecanIntegrinsTumorIn VivoPeptidesComplexReceptorMalignant NeoplasmsCellsExtracellular DomainInhibitor/AntagonistIn VitroSignal TransductionAngiogenesisDiagnosisMouse ModelTumorigenesisCell SurfaceNovel TherapeuticsResistanceFamilyCell SurvivalSiteGrowth
Grant awards (42)
A kinase-independent role for EGFR in p38MAPK suppression and S-phase progression in head and neck cancer$454,116
R01 · FY2022 · DE · contact PI
A kinase-independent role for EGFR in p38MAPK suppression and S-phase progression in head and neck cancer$452,656
R01 · FY2021 · DE · contact PI
Syndecan-1 (CD138) and its synstatins: targeting invasion, survival and angiogenesis in myeloma$369,666
R01 · FY2021 · CA · contact PI
A kinase-independent role for EGFR in p38MAPK suppression and S-phase progression in head and neck cancer$480,603
R01 · FY2020 · DE · contact PI
Syndecan-1 (CD138) and its synstatins: targeting invasion, survival and angiogenesis in myeloma$369,666
R01 · FY2020 · CA · contact PI
Project 3: Targeting Head and Neck Cancer with Synstatin Therapeutics$247,093
P50 · FY2020 · DE · contact PI
Syndecan-1 (CD138) and its synstatins: targeting invasion, survival and angiogenesis in myeloma$358,575
R01 · FY2019 · CA · contact PI
Project 3: Targeting Head and Neck Cancer with Synstatin Therapeutics$252,539
P50 · FY2019 · DE · contact PI
Syndecan-1 (CD138) and its synstatins: targeting invasion, survival and angiogenesis in myeloma$369,666
R01 · FY2018 · CA · contact PI
Project 3: Targeting Head and Neck Cancer with Synstatin Therapeutics$265,051
P50 · FY2018 · DE · contact PI
Signaling role of syndecans in HER2+ and triple negative breast cancer$400,210
R01 · FY2017 · CA · contact PI
Syndecan-1 (CD138) and its synstatins: targeting invasion, survival and angiogenesis in myeloma$375,552
R01 · FY2017 · CA · contact PI
Project 3: Targeting Head and Neck Cancer with Synstatin Therapeutics$266,777
P50 · FY2017 · DE · contact PI
Signaling role of syndecans in HER2+ and triple negative breast cancer$400,210
R01 · FY2016 · CA · contact PI
Project 3: Targeting Head and Neck Cancer with Synstatin Therapeutics$266,777
P50 · FY2016 · DE · contact PI
Signaling role of syndecans in HER2+ and triple negative breast cancer$400,210
R01 · FY2015 · CA · contact PI
Signaling role of syndecans in HER2+ and triple negative breast cancer$388,203
R01 · FY2014 · CA · contact PI
Synstatin Therapy for Multiple Myeloma$377,380
R01 · FY2014 · CA · contact PI
Signaling role of syndecans in HER2+ and triple negative breast cancer$368,264
R01 · FY2013 · CA · contact PI
Synstatin Therapy for Multiple Myeloma$365,709
R01 · FY2013 · CA · contact PI
Synstatin Therapy for Multiple Myeloma$389,053
R01 · FY2012 · CA · contact PI
Synstatin Therapy for Multiple Myeloma$389,052
R01 · FY2011 · CA · contact PI
Synstatin Therapy for Multiple Myeloma$418,831
R01 · FY2010 · CA · contact PI
Regulation of angiogenesis by syndecan-1$249,376
R01 · FY2009 · CA · contact PI
Regulation of angiogenesis by syndecan-1$249,491
R01 · FY2008 · CA · contact PI
Proteoglycans of the Plasma Membrane$248,329
R01 · FY2008 · CA · contact PI
Regulation of angiogenesis by syndecan-1$249,604
R01 · FY2007 · CA · contact PI
Proteoglycans of the Plasma Membrane$248,329
R01 · FY2007 · CA · contact PI
Proteoglycans of the Plasma Membrane$255,745
R01 · FY2006 · CA · contact PI
Regulation of angiogenesis by syndecan-1$252,569
R01 · FY2006 · CA · contact PI
2006 Proteoglycans Gordon Research Conferences$25,000
R13 · FY2006 · AR · contact PI
Role of Heparan Sulfate in FGF Action$263,445
R01 · FY2005 · GM
Proteoglycans of the Plasma Membrane$261,900
R01 · FY2005 · CA
Role of Heparan Sulfate in FGF Action$263,445
R01 · FY2004 · GM
Proteoglycans of the Plasma Membrane$234,589
R01 · FY2004 · CA
Role of Heparan Sulfate in FGF Action$263,445
R01 · FY2003 · GM
PROTEOGLYCANS OF THE PLASMA MEMBRANE$234,691
R01 · FY2003 · HD
Role of Heparan Sulfate in FGF Action$288,104
R01 · FY2002 · GM
PROTEOGLYCANS OF THE PLASMA MEMBRANE$227,854
R01 · FY2002 · HD
PROTEOGLYCANS OF THE PLASMA MEMBRANE$221,220
R01 · FY2001 · HD
PROTEOGLYCANS OF THE PLASMA MEMBRANE$214,773
R01 · FY2000 · HD
HEPARAN SULFATE AND FGF ACTION$196,170
R01 · FY2000 · GM